DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Endroit courant :
>
> This Story


Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment

 

 

Business Affairs Homepage

Medmo lets patients set price for radiology imaging tests A travel industry concept comes to healthcare

Bruker in deal to acquire JPK Instruments JPK makes microscopy instruments for biomolecular and cellular imaging

First radiology center opens in Zimbabwe capital to help curb shortage Currently 115 radiologists in country of 14 million people

Onkos Surgical and Insight Medical partner to bring augmented reality to tumor surgery Could this become the new standard of care?

Veritas closes $1 billion GE Healthcare software unit buy Will run newly acquired business as a stand-alone company

Praxair in deal to sell European assets to Taiyo Nippon Sanso Move is dependent on the successful closing of the Praxair-Linde merger

Precision X-Ray and Faxitron Bioptics combine business assets Forming a new global leader in biological irradiation

DaVita hit with $383.5 million jury verdict in dialysis death suit Three patients suffered cardiac arrest after getting GranuFlo therapy

Ultrasound Versus IR: Making decisions about real-time location systems Doing your homework is key to making the right investment in RTLS

Alliance completes deal for Piramal Imaging Expanding market presence in molecular imaging

Philips to halt production of external defibrillators in two U.S. facilities

par Lauren Dubinsky , Senior Reporter
Philips North America LLC announced on Wednesday that it will suspend the production of external defibrillators at its operations in Andover, Massachusetts and Bothell, Washington.

These are the terms of a consent decree the company reached with the U.S. government.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"Following FDA inspections at the Andover and Bothell facilities from 2009 to 2015, FDA investigators made observations regarding Philips' compliance with the Good Manufacturing Practices and medical device reporting requirements of the Food, Drug and Cosmetic Act, with a focus on how Philips addressed issues of its defibrillators," Carla Kriwet, chief business leader of connected care and health informatics at Philips, told HCB News.

The facilities will resume production once FDA inspections confirm that they comply with the Quality System Regulation. Philips has already taken steps to restructure its company-wide Q&R function with new Q&R leadership, reporting lines, training and culture change initiatives.

"Philips takes this matter extremely seriously," said Kriwet. "The company is committed to fulfilling the terms of the Consent Decree, and we have already taken actions since 2015 to address this."

She added that Philips defibrillators currently in use are recommended to remain in use because the company found no reason to believe they pose a risk to patients.

The facilities are still permitted to manufacture and distribute certain automated external defibrillator models, including its HeartStart HS1 AEDs. The company will also continue to service devices in its emergency care and resuscitation portfolio, and provide consumables and relevant accessories.

In 2014, Philips was involved in a similar situation with the FDA that concerned medical scanners at its factories in Cleveland, Ohio. CEO Frans van Houten told Reuters that the current situation is different because Philips had invested in quality control in recent years.

“We have made tremendous progress since 2015 but that didn’t matter,” he said. “This is a consequence of past sins.”

As a result of the decree, Philips expects a loss of about EUR 20 million in the fourth quarter of this year, and about EUR 60 million in 2018. That’s mostly due to the suspension of production, profit disgorgement payments, and incremental costs to prepare for and handle the regulatory inspections.

Back to HCB News
  Pages: 1

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Publicité
Développez la notoriété de votre marque
Enchères + Ventes Privées
Obtenir le meilleur prix
Acheter des équipement / pièces
Trouver le meilleur prix
Infos du jour
Lire Les dernières nouvelles
Annuaire
Consulter tous les utilisateurs DOTmed
Éthique concernant DOTmed
Voir notre programme d'éthique
L'or partie le programme de fournisseur
Recevoir des demandes PH
Programme de marchand de service d'or
Recevoir des demandes
Fournisseurs de soins de santé
Voir tous les outils des HCP (abréviation pour les professionnels de la santé)
Les travaux/Formation
Trouver / combler un poste
Parts Hunter +EasyPay
Obtenir des devis de pièces
Certification Récentes
Voir les utilisateurs récemment certifiés
Evaluation Récentes
Voir les utilisateurs récemment certifiés
Central de location
Louer de l’équipement à moindre prix
Vendre des équipements / pièces
Obtenir le maximum d'argent
Service le forum de techniciens
Trouver de l'aide et des conseils
Simple demande de propositions
Obtenir des devis pour des appareils
Expo Virtuelle
Trouver des services d'appareils
L'Access et l'utilisation de cet emplacement est sujet aux modalités et aux conditions du notre de nos MENTIONS LEGALES & DONNEES PERSONELLES
Propriété de et classe des propriétaires DOTmedà .com, inc. Copyright ©2001-2018 DOTmed.com, Inc.
TOUS DROITS RÉSERVÉS